Our two large randomized clinical studies clearly show that decreasing CRP as opposed to an increase in CRP post-atezolizumab treatment is a marker of good outcome for patients on anti-PD-L1 therapy in second line NSCLC and also re-affirms that pre-treatment elevated CRP is a marker of poor prognosis in NSCLC. The gene discussed is CRP; the disease is non-small cell lung carcinoma.